ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
FTSE 100
8,433.76
0.63%
Dow Jones
39,512.84
0.32%
Gold vs US Dollar
2,356.625
-0.15%
Brent Oil
82.345
-0.05%
Bitcoin
60,878.42
-0.93%
Pepperstone
Advertisement
Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Lixte Biotechnology Holdings Inc (LIXT)

  7. Lixte Biotechnology Holdings Inc (LIXT) News

Lixte Biotechnology (LIXT)

Lixte Biotechnology Holdings Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:LIXT
DateTimeSourceHeadlineSymbolCompany
08/05/202414:25GlobeNewswire Inc.LIXTE Biotechnology Co-Sponsoring International Scientific Conference on “Therapeutic Over-Activation in Cancer”NASDAQ:LIXTLixte Biotechnology Holdings Inc
24/04/202420:25AllPennyStocks.comMixed Shelf Filing Gives Micro Cap Delayed BoostNASDAQ:LIXTLixte Biotechnology Holdings Inc
27/03/202419:35AllPennyStocks.comBiotech Steals The Show Following Pre-Clinical Data AnnouncementNASDAQ:LIXTLixte Biotechnology Holdings Inc
27/03/202412:30GlobeNewswire Inc.NEW SCIENTIFIC PUBLICATION SHOWS LB-100, LIXTE’S LEAD CLINICAL COMPOUND, CAN FORCE CANCER CELLS TO GIVE UP THEIR CANCER-CAUSING PROPERTIESNASDAQ:LIXTLixte Biotechnology Holdings Inc
21/03/202412:30GlobeNewswire Inc.LIXTE Provides Update on Progress with LB-100 as a PP2A Inhibitor to Enhance Chemotherapy and Immunotherapy Cancer TreatmentsNASDAQ:LIXTLixte Biotechnology Holdings Inc
27/02/202421:59Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:LIXTLixte Biotechnology Holdings Inc
27/02/202413:30GlobeNewswire Inc.Professor René Bernards to Present New Pre-Clinical Data on LIXTE’s LB-100 at Joint Conference of European and American Associations for Cancer ResearchNASDAQ:LIXTLixte Biotechnology Holdings Inc
26/02/202415:48Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:LIXTLixte Biotechnology Holdings Inc
26/02/202413:30GlobeNewswire Inc.LIXTE Biotechnology Enters into Exclusive Immune Oncology Patent License Agreement with NINDS and NCINASDAQ:LIXTLixte Biotechnology Holdings Inc
29/01/202413:30GlobeNewswire Inc.First Patient Dosed with LIXTE’s LB-100 and GSK’s Immunotherapy Dostarlimab-gxly in Ovarian Clear Cell Carcinoma TrialNASDAQ:LIXTLixte Biotechnology Holdings Inc
28/11/202322:21Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:LIXTLixte Biotechnology Holdings Inc
13/11/202319:28Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:LIXTLixte Biotechnology Holdings Inc
13/11/202313:30GlobeNewswire Inc.LIXTE Biotechnology Provides Update on Clinical Progress and Expanding CollaborationsNASDAQ:LIXTLixte Biotechnology Holdings Inc
09/11/202322:16Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:LIXTLixte Biotechnology Holdings Inc
17/10/202322:27Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:LIXTLixte Biotechnology Holdings Inc
16/10/202319:51Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LIXTLixte Biotechnology Holdings Inc
16/10/202313:30GlobeNewswire Inc.LIXTE, Netherlands Cancer Institute, and Oncode Institute to Expand CollaborationNASDAQ:LIXTLixte Biotechnology Holdings Inc
10/10/202320:55Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:LIXTLixte Biotechnology Holdings Inc
10/10/202320:47Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:LIXTLixte Biotechnology Holdings Inc
09/10/202313:30GlobeNewswire Inc.LIXTE Biotechnology Holdings Announces the Passing of its Founder, John S. KovachNASDAQ:LIXTLixte Biotechnology Holdings Inc
06/10/202301:39Edgar (US Regulatory)Form 4/A - Statement of changes in beneficial ownership of securities: [Amend]NASDAQ:LIXTLixte Biotechnology Holdings Inc
06/10/202301:36Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LIXTLixte Biotechnology Holdings Inc
04/10/202323:10Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LIXTLixte Biotechnology Holdings Inc
29/09/202321:05Edgar (US Regulatory)Form PRE 14A - Other preliminary proxy statementsNASDAQ:LIXTLixte Biotechnology Holdings Inc
27/09/202311:15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:LIXTLixte Biotechnology Holdings Inc
27/09/202311:05Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LIXTLixte Biotechnology Holdings Inc
26/09/202313:30GlobeNewswire Inc.LIXTE Appoints Bas van der Baan as President and Chief Executive OfficerNASDAQ:LIXTLixte Biotechnology Holdings Inc
20/09/202316:20Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:LIXTLixte Biotechnology Holdings Inc
20/09/202313:30GlobeNewswire Inc.LIXTE Biotechnology Announces a Supported Collaborative Trial to Study LIXTE’s First-in-Class PP2A Inhibitor, LB-100, Plus GSK’s Immunotherapy, Dostarlimab, in Clear-Cell Ovarian CancerNASDAQ:LIXTLixte Biotechnology Holdings Inc
22/08/202305:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:LIXTLixte Biotechnology Holdings Inc
 Showing the most relevant articles for your search:NASDAQ:LIXT

Your Recent History

LSE
QBT
Quantum Blockchain Techn...
LSE
SYME
Supply@me Capital
LSE
TRT
Transense Technologies
LSE
TRIN
Trinity Exploration & Pr...
LSE
XTR
Xtract Resources
LSE
ZTF
Zotefoams
LSE
IQE
Iqe
LSE
PET
Petrel Resources
LSE
W7L
Warpaint London
Delayed Upgrade Clock
    ADVFN Logo

    United Kingdom
    Company
    Business
    Popular
    Get The App

    Support: +44 (0) 203 8794 460 | support@advfn.com

    By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

    © 2024 ADVFN PLC - All Rights Reserved